A detailed history of Fmr LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 10,878 shares of TCRX stock, worth $23,278. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,878
Previous 21,878 50.28%
Holding current value
$23,278
Previous $30,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$1.1 - $1.8 $12,100 - $19,800
-11,000 Reduced 50.28%
10,878 $15,000
Q1 2025

May 12, 2025

BUY
$1.35 - $3.12 $27,577 - $63,735
20,428 Added 1408.83%
21,878 $30,000
Q4 2024

Feb 13, 2025

BUY
$2.93 - $5.94 $3,003 - $6,088
1,025 Added 241.18%
1,450 $4,000
Q3 2024

Nov 13, 2024

BUY
$4.97 - $7.49 $2,112 - $3,183
425 New
425 $2,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $40.5M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.